Platform & Approach

We develop groundbreaking drug + energy device combination therapies to cure cancer

Our Differentiated Approach

BioConvergent Health (BCH) has developed a proprietary approach using drug(s) + energy devices (e.g., radiation and ultrasound) to train the patient’s immune system to kill a patient’s cancer, while maintaining a high quality of life.

Our Platform

Our platform is based on core patented assets licensed from leading pharmaceutical companies, device companies and academic medical institutions.

Major public, global pharmaceutical and device company
Public, clinical stage biotechnology company
Major public, global device company
Academic medical
center recognized for clinical excellence in research, training and delivering patient-centered care

Our Assets Include

  • Exclusive, worldwide licenses to two Phase 2 drugs with clinical POC

  • Breakthrough ultrasound device + drug platform for cancer vaccination

  • Proprietary approaches for integrating drugs, energy devices, and cell therapy to achieve patient outcomes that cannot be achieved with each standalone therapy.